A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Phase 2 Terminated 20 enrolled NYU Langone Health Unicorn Pacific Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side effects.

Timeline

Start: 2011-02
Primary completion: 2013-12
Completion: 2013-12

Outcome

Outcome not reported

Stopped (Business): “due to lack of funding”

Publications

Background Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23. doi: 10.1046/j.1365-2141.1998.00930.x. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TBL12	Unknown	40 ml	Oral